Taking the mat is Judo Bio, an up-and-coming biotech armed with $100 million to develop oligonucleotide medicines targeting ...

The FDA has granted Fast Track designation to zilganersen for the treatment of Alexander disease, a rare type of leukodystrophy.

Avidity Biosciences, Inc. surges on positive developments in AOCs for muscular disorders, strategic partnerships, and ...

Oral presentation: “Oligonucleotide guided RNA editing of SLC10A1 (NTCP) as a therapeutic approach to lower bile acid re-uptake in cholestatic diseases” Following OTS, the slide deck will be available ...

A study led by researchers of the Institute of Biomedicine of the University of Barcelona (IBUB) has developed a new ...

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced the company’s launch and $100 million in initial financing, including seed financing and ...

Newly launched Judo Bio aims to develop ligand-siRNA conjugates through its Selectively Targeting RNA Into KidnEy (STRIKE) ...

Avidity Biosciences excels in antibody oligonucleotide conjugates with its stock tripling in the past year due to innovative ...

Venkat Krishnamurthy, Ph.D., Senior Vice President, Head of Platform at Korro, will deliver an oral presentation on KRRO-110, the Company’s first development candidate for the potential treatment of ...